1 Title: The Individual and Social Determinants of COVID-19 in Ontario, Canada: A 2 Population-Wide Study 3 Authors: Maria E. Sundaram, PhD¹, Andrew Calzavara, MS¹, Sharmistha Mishra*, MD, 4 PhD^{2,3,4,5}, Rafal Kustra, PhD^{6,7}, Adrienne K. Chan, MD^{2,3,6,8}, Mackenzie A. Hamilton, BS^{1,6}, Mohamed Djebli, BS^{1,6}, Laura C. Rosella, PhD^{1,6}, Tristan Watson, MPH^{1,6}, Hong 5 6 Chen, PhD^{1,6,9}, Branson Chen, MSc¹, Stefan D. Baral*, MD¹⁰, Jeffrey C. Kwong*, 7 $MD^{1,6,9,11,12}$ 8 9 10 Author affiliations: ¹ ICES, Toronto, ON 11 ² Department of Medicine, University of Toronto, Toronto, ON 12 ³ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, 13 14 ⁴ Institute of Medical Science, University of Toronto, Toronto, ON 15 16 ⁵ MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto 17 ⁶ Dalla Lana School of Public Health, University of Toronto, Toronto, ON 18 ⁷ Department of Statistical Sciences, University of Toronto, Toronto, ON 19 ⁸ Sunnybrook Health Sciences Centre, Toronto, ON 20 ⁹ Public Health Ontario, Toronto, ON 21 22 ¹⁰ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 23 Baltimore, MN ¹¹ Department of Family and Community Medicine, University of Toronto, Toronto, ON 24 ¹² University Health Network, Toronto, ON 25 * Equal contribution 26 27 28 Corresponding author: Jeff Kwong, MD 29 30 Word count: 2989 (not counting abstract, figures, & tables) 31 32 33 Abstract word count: 347 34 35 Key Points word count: 101

Key PointsQuestion: What are the social determinants of health that contextualize individual-level risks for coronavirus disease 2019 (COVID-19), and how do selection biases affect our understanding of these risks?
Findings: In this province-wide observational study of 14.7 million Canadians, social determinants related to housing, education, and recent immigration were associated with increased COVID-19 risks, with little evidence of selection bias. Individual factors, such as underlying health conditions, were more prone to selection bias using certain analytic approaches.
Meaning: Social determinants of health appear to drive COVID-19 incidence in Ontario, Canada. Interventions aiming to prevent COVID-19 transmission should address these empiric structural risks.

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Abstract Importance: Optimizing the public health response to reduce coronavirus disease 2019 (COVID-19) burden necessitates characterizing population-level heterogeneity of COVID-19 risks. However, heterogeneity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing may introduce biased estimates depending on analytic design. Objective: Characterizing individual, environmental, and social determinants of SARS-CoV-2 testing and COVID-19 diagnosis. Design: We conducted cross-sectional analyses among 14.7 million people comparing individual, environmental, and social determinants among individuals who were tested versus not yet tested. Among those diagnosed, we used three analytic designs to compare predictors of: 1) individuals testing positive versus negative; 2) symptomatic individuals testing positive versus negative; and 3) individuals testing positive versus individuals not testing positive (i.e. testing negative or not being tested). Analyses included tests conducted between March 1 and June 20, 2020. Setting: Ontario, Canada. Participants: All individuals with ≥1 healthcare system contact since March 2012, excluding individuals deceased before, or born after, March 1, 2020, or residing in a long-term care facility.

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Exposures: Individual-level characteristics (age, sex, underlying health conditions, prior healthcare use), area-based environmental (air pollution) exposures, and area-based social determinants of health (income, education, housing, marital status, race/ethnicity, and recent immigration). Main Outcomes and Measures: Odds of SARS-CoV-2 test, and of COVID-19 diagnosis. Results: Of a total of 14,695,579 individuals, 758,691 had been tested, of whom 25,030 (3.3%) tested positive. The further the odds of testing from the null, the more variability observed in the odds of diagnosis across analytic design, particularly among individual factors. There was less variability in testing by social determinants across analytic design. Residing in areas with highest household density (adjusted odds ratio: 2.08; 95%CI: 1.95-1.21), lowest educational attainment (adjusted odds ratio: 1.52; 95%CI: 1.44-1.60), and highest proportion of recent immigrants (adjusted odds ratio: 1.12; 95%CI: 1.07-1.16) were consistently related to increased odds of COVID-19 across analytic designs. Conclusions and Relevance: Where testing is limited, risk factors may be better estimated using population comparators rather than test-negative comparators. Optimizing COVID-19 responses necessitates investment and sufficient coverage of structural interventions tailored to heterogeneity in social determinants of risk, including household crowding and systemic racism.

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Introduction The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), has resulted in a pandemic with heterogeneity in exposure and transmission risks. 1-4 There has been greater focus on characterizing individual determinants of COVID-19, such as age. 2,5 sex. 6,7 and underlying health conditions, ^{2,8} than on social determinants of health.⁹ Heterogeneity in social determinants of COVID-19 may exist at the individual and network levels (for example, by housing density¹⁰⁻¹²). In addition, social determinants including barriers to healthcare, systemic racism, and xenophobia have been implicated in COVID-19 risk. 13,14 Environmental determinants such as ambient air pollution may also play a role, as existing evidence indicates that higher ambient air pollution increases risk for infection with other respiratory viruses. 15 While previous studies suggest that air pollution may be biologically related to COVID-19. 16 including severe COVID-19,^{17,18} it may also play a role in COVID-19 risk by operating within the context of low-quality housing and environmental racism. 19,20 Using observational data to identify determinants of COVID-19 relies on SARS-CoV-2 testing, which is not equally distributed. Differential testing introduces the potential for selection biases, ^{21,22} including collider bias. ²² Collider bias may be introduced into observational studies if the determinants under investigation are related to both COVID-19 and the likelihood of testing. 22-24

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Thus, to identify heterogeneity across potential determinants of COVID-19, we examined individual, environmental, and social determinants associated with SARS-CoV-2 testing and diagnoses among 14.7 million individuals in Ontario, Canada. We compared three analytic approaches to examine the role of selection biases.²² Methods Study population, setting, and design We conducted an observational study using population-based laboratory and health administrative databases from Ontario, Canada. Ontario has a single-payer health system that provides universal access to hospital and physician services²⁵ and laboratory testing. ²⁶ We used data from individuals tested between March 1 and June 20, 2020 to identify determinants associated with testing, and then used three analytic designs to identify determinants associated with laboratory-confirmed diagnosis of COVID-19. Data sources, linkages, and inclusion criteria We linked individual-level SARS-CoV-2 testing data from the Ontario Laboratories Information System (OLIS) to relevant health-related datasets containing demographic, healthcare use, and area-level information (eTable 1). These datasets were linked using unique encoded identifiers and analyzed at ICES, a not-for-profit research institute in Ontario.²⁷

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

OLIS captured approximately 88% of all laboratory-confirmed COVID-19 cases reported by the province during the study period. OLIS records included specimen collection date, results, and a text field for symptoms completed by healthcare providers at the time of sampling. We obtained individual- and area-level demographic and environmental information from the Registered Persons Database; the Canadian Institute for Health Information's Discharge Abstract Database, Same Day Surgery Database, and National Ambulatory Care Reporting System; the Ontario Health Insurance Program; the Ontario Mental Health Reporting System; the Ontario Population Health and Environment Cohort; and the 2016 Canadian Census.²⁸ Further details are available below and in eTable 1. To assess community transmission risks, we included individuals who were tested for SARS-CoV-2 by polymerase chain reaction tests and were not residing in a long-term care facility as of March 1, 2020 (Figure 1). For individuals with more than one test in OLIS, we used the first positive or indeterminate test, or the first negative test if all tests during the study period were negative. Never-tested individuals during the study period were included if they were not recorded as deceased before, or born after, March 1, 2020, and were not residing in a long-term care facility. A diagram of individuals included and excluded is shown in Figure 1. Selection and definition of potential determinants of COVID-19 diagnoses Individual-level determinants included sex, age group, underlying health conditions, and prior healthcare use (eTable 1). Underlying health conditions were selected as: a)

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

health conditions identified in the literature as associated with COVID-19 severity^{2,29-32} or associated with symptoms similar to those caused by COVID-19, because severity and symptoms may lead to differential testing and thus, selection bias:33-38 or b) health conditions such as dementia that increase the need for personal care support, thereby reflecting network-level contact patterns that intersect with occupational risks among essential care providers. 39,40 Healthcare use was hypothesized to increase access to testing, and/or signal a marker for comorbidities, and was measured by number of hospital admissions in the past 3 years; number of outpatient physician visits in the past year; and influenza vaccination in the 2019-2020 season. We also included ACG® System⁴¹ Aggregated Diagnostic Groups (ADGs)⁴² as a composite measure of comorbidities. Environmental determinants included fine particulate matter (PM_{2.5}) using satellitederived estimates⁴³ and land-use regression model for NO₂,⁴⁴ at the postal-code level. Social determinants were conceptualized as area-based variables that may signal contact rates within and/or outside households [household density, uncoupled (for example, not married) status]; 45,46 socio-economic barriers to healthcare access and/or housing or proxies of occupation (household income, educational attainment, apartment building density, and social assistance):^{47,48} and unmeasured confounders related to race/ethnicity (visible minority status and recent immigration). 13,14 These determinants were derived from available measures within the long-form 2016 Canada Census at the

level of dissemination areas (DA), which are the smallest geographic unit that Census data are disseminated. ⁴⁹ DAs were ranked at the city level (for median per-person income equivalent) or at the province level (for all other social determinants), and then categorized into quintiles. For apartment building density and recent immigration, the high frequency of zeros permitted the creation of only three categories (i.e., comparing the fourth and fifth quintiles with the lowest 60%). Variable definitions are detailed in **eTable1**.

Statistical analysis

To identify determinants of testing, the outcome was defined as receipt of at least one SARS-CoV-2 test during the study period. The comparator group comprised Ontario residents who did not have a record of testing during the study period. Determinants of testing were examined in unadjusted, age/sex-adjusted, and fully-adjusted logistic regression models that included all determinants. The fully-adjusted model also included a fixed-effect covariate for public health region. These are geographic areas in which public health measures were differentially applied⁵⁰ and along which there may be considerable variability in measured and unmeasured social determinants.⁵¹ We opted to include public health regions *a priori* in the model due to these predicted variations in public health response.

To identify determinants of COVID-19, the outcome variable was a laboratory-confirmed diagnosis. To explore the potential for effects of a variety of sources of bias from testing, we compared the results according to different comparison sub-groups, by

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

characteristics that may have influenced the probability of being tested. We first compared individuals who tested positive to individuals who tested negative ("pseudotest-negative design"). Second, we restricted the analysis to individuals with symptomatic illness, mirroring the test-negative design commonly used to assess influenza vaccine effectiveness (the "true test-negative design"). 52 Third, we compared all individuals who tested positive to all individuals who did not test positive (i.e., to individuals who tested negative or were not tested: the "case-control design"). Potential mechanisms of selection biases in each analytic design are outlined in eFigure 1A-C. We then conducted unadjusted, age/sex-adjusted, and fully-adjusted logistic regression models (including all determinants and public health region, as with testing) using each of the three analytic approaches to identify heterogeneity in individual, environmental, and social determinants of COVID-19 diagnosis. We interpreted each set of determinants (individual, environmental, social) as independent analyses based on the directed acyclic graphs (eFigure 1A-C). Statistical analyses were conducted using SAS v. 9.4 (Cary, NC). Ethical review The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a Research Ethics Board. Results

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

Of 758,691 individuals tested during the study period, 25,030 (3.3%) received a laboratory-confirmed diagnosis (**Figure 1**). Only 11.8% of those tested had a symptom recorded by the provider, 13.6% were considered asymptomatic, and 74.6% were missing symptom information. **Table 1** describes the characteristics of the study population. Determinants of SARS-CoV-2 testing In fully-adjusted analyses, odds of testing increased with age (Table 2). Males had lower odds of testing than females. Nearly every underlying health condition was associated with increased odds of testing, as were most measures of prior healthcare use. In contrast, higher measures of ambient air pollution were associated with reduced odds of testing. There was little variability in the odds of testing by most area-based social determinants. However, areas with higher visible minority populations had lower odds of testing, whereas areas with higher household income and greater percentages of uncoupled individuals had higher odds of testing. Effect measures across nearly all determinants appeared to be progressively attenuated from unadjusted, to age/sexadjusted, to fully-adjusted regression models (eTable 2). Variability in determinants of COVID-19 diagnosis across three analytic approaches Choice of analytic design and comparison group restrictions had substantial influences on the magnitude and direction of the association between individual-level determinants and diagnosis (Table 2). Determinants associated with odds of testing further from the null appeared to be more variable in terms of odds of diagnosis across analytic designs.

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

For example, the odds of testing for adults aged ≥85 years compared to those aged <5 years deviated considerably from the null (adjusted odds ratio [aOR]=5.57; 95%CI. 5.45-5.70), and the odds of diagnosis differed between the pseudo-test-negative design (aOR=1.72; 95%CI, 1.48-2.01), the true test-negative design (aOR=5.95; 95%CI, 3.57-9.92), and the case-control design (aOR=7.09; 95%CI, 6.08-8.26). Some health conditions associated with higher odds of testing, such as chronic respiratory conditions, and indicators of prior healthcare use appeared protective against COVID-19 using the pseudo-test-negative design, but reverted to the null or showed increased odds of diagnosis using the case-control design. As with testing, effect measures for COVID-19 diagnosis across all determinants appeared to be progressively attenuated from unadjusted, to age/sex-adjusted, to fully-adjusted regression models (eTables 3-5). Individual determinants of COVID-19 diagnosis using the case-control design Using the case-control design, age, certain comorbidities (e.g., hypertension, diabetes, dementia), and increased prior healthcare use were associated with increased odds of COVID-19. In contrast, other comorbidities (e.g., cancer, substance abuse) and receipt of influenza vaccine in the 2019-2020 season were associated with reduced odds of diagnosis (Table 2). Environmental determinants of COVID-19 diagnosis using the case-control design The two highest categories of PM_{2.5} exposure were associated with increased odds of diagnosis, whereas no categories of exposure to NO₂ were associated with increased odds of diagnosis consistently across analytic approaches.

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

Social determinants of COVID-19 diagnosis using the case-control design Area-level social determinants independently associated with COVID-19 included higher household income, increased receipt of social assistance, lower educational attainment, greater percentages of uncoupled individuals, higher household density, increased apartment building density, and greater percentages of recent immigrants. Figures 2A and 2B highlight the changes from unadjusted to fully-adjusted models for the associations between area-level social determinants and testing and diagnosis, respectively. For testing, the associations were attenuated after adjustment for nearly all determinants. The association for household income reversed direction following adjustment. For diagnosis, the associations were attenuated after adjustment for all social determinants except for household density. Similar to testing, the association with COVID-19 for household income reversed direction following adjustment. **Discussion** In this large-scale, population-based study, we identified social determinants as key potential determinants for a diagnosis of COVID-19. We identified variability in associations, likely due to selection biases, by analytic design across individual determinants of COVID-19 diagnosis. We identified increased odds of diagnosis associated with household density, educational attainment, uncoupled status, and recent immigration, consistent with

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

findings from other settings. 51,53,54 In particular, the results concerning social determinants and COVID-19 risk presented here suggest these social determinants are not likely artifacts of selection bias from study design, given the consistency of findings across different analytic approaches. Lower educational attainment or uncoupled status may be associated with higher exposure risk through lower-paying jobs in the service industry⁵⁵ and/or other high-exposure occupations, either because those jobs cannot be done feasibly with proper protections, or because protective policies fail to be issued, leaving workers at high risk. 56,57 Higher percentages of recent immigrants in an area were associated with COVID-19 diagnosis, even after adjustment, although the percentage of visible minorities was not. Both variables might represent residual measures of mediators of systemic racism, potentiating relative risks of SARS-CoV-2 exposure and COVID-19 severity, 58-60 including COVID-19-related hospitalization/death. 14,21,30,54 We found that an association between visible minority and COVID-19 diagnosis in Ontario was attenuated after adjustment for individual, environmental, and other social determinants. These findings likely reflect what is already known about race and ethnicity as social constructs and social determinants of health. 61 This is further supported by the attenuation of effect estimates from the unadjusted, to age/sex-adjusted, to fully-adjusted models. Finally, the fact that there was little variation in the odds of testing rates across levels of most of the social determinants suggests that testing resources may not be prioritizing those who are most at risk.⁶² However, even with this finding, our results indicate that social determinants of health play important roles in determining COVID-19 risk. Taken together, our findings suggest a need to increase and/or redirect resources that specifically address social

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

determinants such as household density^{48,63} (e.g., voluntary temporary isolation hotels⁶⁴), proxies for occupational risk^{56,60} (e.g., paid sick leave⁶⁵), and other mediators of systemic racism^{62,66,67} (e.g. community-led outreach testing⁶⁸). We also identified the size and direction of influence that selection biases may have, adding to the ongoing conversation on the challenges of interpreting determinants for COVID-19 due to collider bias.²² Although we did not directly explore each potential collider mechanism, the pattern that emerged was that underlying health conditions associated with COVID-19 severity² may have been prone to collider bias, as evidenced by higher testing and a seemingly protective effect when using the test-negative designs that reversed when using the case-control design. It is, however, also possible that a high number of covariates in fully-adjusted models caused instability in effect measure estimates for these covariates. Age also demonstrated a similar potential susceptibility to collider bias, possibly mediated by COVID-19 severity and symptoms (i.e., older age groups are more likely to develop severe/symptomatic infection if infected²). Over the study period, the testing criteria in Ontario shifted from returning symptomatic travellers to severely symptomatic individuals and those with occupational exposure to additional testing of asymptomatic individuals. 33-36,38 In our study, the restriction of the testnegative design to symptomatic individuals did not yield substantially different results than the test-negative design including symptomatic and asymptomatic individuals, but that may have been partly due to the extensive (74.6%) missingness of symptom reporting in the testing data. We opted not to use multiple imputation methods to determine symptom information because, at the time the analysis was conducted,

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

reported symptoms of COVID-19 were highly variable and the extent to which individuals may have asymptomatic or pre-symptomatic illness was unclear, limiting our confidence in the generalizability of existing information to individuals whose information was missing. Thus, while there is an intuitive desire to compare test positivity rates among those tested—a common metric of comparison across surveillance reports and dashboards^{69,70}—the risks of erroneously identifying a "risk/protective factor". particularly individual determinants such as underlying health conditions, sex, and age, are high and deserve careful interpretation by examining, as best possible, the reasons for testing. ²² In the context of low overall levels of testing, the case-control design may have mitigated some potential sources of selection bias, with the assumption that those not tested are similar to those who tested negative. 21,22 Additionally, we found that some underlying health conditions and prior healthcare use remained associated with diagnoses, reflecting either unmeasured confounders or possible biological susceptibility to infection if exposed; 15,16,71-73 and suggesting that strategies tailored to reduce exposures among individuals characterized by these individual determinants could also be important in risk-tailored prevention. Finally, these analyses identified PM_{2.5} as being related to the odds of COVID-19. It is likely that some of this effect is due to underlying social determinants of health and access to tests. Air pollution is often more intense, and results in worse health outcomes, in areas with higher social deprivation. 74,75 However, existing studies have also implicated environmental pollution as having a biological relationship to the risk and severity of COVID-19 and other respiratory infections. 15,16,19 Taken together with other

findings regarding social determinants of health, these results indicate the importance of considering air pollution and particulate matter in both individual- and area-directed COVID-19 interventions.

Limitations

Our diagnoses were restricted to laboratory-confirmed cases and to the 88% of diagnoses available via OLIS, and thus could miss probable cases as well as the remaining laboratory-confirmed cases that may have different determinants of infection.

Results are also conditioned on the assumption that determinants remained constant across the study period, whereas surveillance data suggest shifts in how infections propagate between social networks. ⁷⁶ Future analyses include examining changes in the direction and magnitude of determinants over the course of the outbreak. Although we generated directed acyclic graphs for the general categories of determinants to help conceptualize and mitigate selection bias while also identifying plausible determinants, it is possible that we over-adjusted when interpreting individual variables within each category. ⁷⁷ Our models also adjusted for public health region, within which many social determinants cluster ⁵¹, and thus we cannot infer from the results presented how social determinants of COVID-19 risk may vary between and within these geographic regions. Social determinants were measured at the area level and were not available at the individual level; however, by describing individuals' neighbourhoods, analyses reflect the role of structural and environmental determinants for individuals living amongst them. Some important determinants identified in the prior literature, such as obesity. ^{8,78} were

not available for our study.⁷⁹ Others, such as occupation, were not included due to uncertainty related to quantifying and appropriately grouping the occupational classifications available in the Census data at the area level.

Conclusion

Individual-level risks for COVID-19 defined by demographic and health-related determinants representing general targets of current response strategies appear to be subject to selection bias, including collider bias. Moving forward and advancing the response necessitates characterizing and addressing the social determinants potentiating heterogeneity in COVID-19 acquisition and transmission risks with risk-tailored, community-based interventions to reduce COVID-19 burden.

Funding Statement

This study was funded by the St. Michael's Hospital Research Innovation Council COVID-19 Research Grant, and research operating grant (VR5 -172683) from the Canadian Institutes of Health Research. SM is supported by a Tier 2 Canada Research Chair in Mathematical Modeling and Program Science. JCK is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The study sponsors did not participate in the design and conduct of the study; collection, management, analysis

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. **Disclaimers:** The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer Care Ontario (CCO). However, the analyses, conclusions, opinions, and statement expressed herein are those of the authors, and not necessarily those of CIHI or CCO. No endorsement by ICES, MOHLTC, CIHI, or CCO is intended or should be inferred. Acknowledgements: We thank IMS Brogan Inc. for use of their Drug Information Database. Finally, we are grateful to the 14.7 million Ontario residents without whom this research would be impossible. **Author contributions:** JK, SM, and SB designed the study. ACa conducted all data analyses (dataset and variable creation and statistical modeling). JK, SM, SB, RK, ACa designed the analyses plans and conducted variable selection, with input from HC and ACK on variable selection and definitions. MAH, MD, LCR, TW contributed to analytic plans related to collider bias. BC contributed to data analyses and data preparation for the symptomatic dataset. MS prepared the figures. MS, JK, SB, and SM wrote the manuscript. All authors interpreted the data and critically reviewed and edited the manuscript.

References

441

442

- Mishra S, Kwong JC, Chan AK, Baral SD. Understanding hetergeneity to inform public health response to COVID-19 in Canada. *Can Med Assoc J.* 2020;192(25):E684-E685.
- Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva, Switzerland: World Health Organization; 16-24 February, 2020
 2020.
- Rosenberg ES, Dufort EM, Blog DS, et al. COVID-19 Testing, Epidemic Features,
 Hospital Outcomes, and Household Prevalence, New York State-March 2020.
 Clinical infectious diseases: an official publication of the Infectious Diseases
 Society of America. 2020.
- 453 4. Jing Q-L, Liu M-J, Yuan J, et al. Household secondary attack rate of COVID-19 and associated determinants. *medRxiv pre-print*. 2020.
- 455
 456
 456
 457
 CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children —
 450
 451
 452
 453
 454
 455
 456
 457
 457
 457
 458
 459
 459
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 <l
- 458 6. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature*. 2020.
- Stall NM, Wu W, Lapointe-Shaw L, et al. Sex- and age-specific differences in COVID-19 testing, cases and outcomes: a population-wide study in Ontario, Canada. *J Am Geriatr Soc.* 2020.
- Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism.* 2020;108:154262.
- 467 9. Abrams E, Szefler S. COVID-19 and the impact of social determinants of health.
 468 The New England journal of medicine. 2020;382(21):2061-2063.
- 469 10. Bhala N, Curry G, Martineau AR, Agyemang C, Bhopal R. Sharpening the global focus on ethnicity and race in the time of COVID-19. *The Lancet.*
- 471 11. Chung H, Fung K, Ferreira-Legere LE, et al. COVID-19 Laboratory Testing in
 472 Ontario: Patterns of Testing and Characteristics of Individuals Tested, as of April
 473 30, 2020. ICES Ontario;2020.
- 474 12. Wang L, Mishra S. *The distribution of cumulative COVID-19 cases in Ontario by* 475 acquisition type over time. 2020.
- 476 13. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *The New England journal of medicine*. 2020;382(26):2534-2543.
- 479 14. Yehia BR, Winegar A, Fogel R, et al. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals. *JAMA Netw Open.* 2020;3(8):e2018039.
- 482 15. Feng C, Li J, Sun W, Zhang Y, Wang Q. Impact of ambient fine particulate matter (PM2.5) exposure on the risk of influenza-like-illness: a time-series analysis in Beijing, China. *Environ Health.* 2016;15:17.

- 485 16. Zoran MA, Savastru RS, Savastru DM, Tautan MN. Assessing the relationship 486 between surface levels of PM2.5 and PM10 particulate matter impact on COVID-487 19 in Milan, Italy. *Sci Total Environ.* 2020;738:139825.
- 488 17. Wu X, Nethery RC, Sabath BM, Braun D, Dominici F. Exposure to air pollution 489 and COVID-19 mortality in the United States: A nationwide cross-sectional study. 490 medRxiv. 2020.
- 491 18. Liang D, Shi L, Zhao J, et al. Urban Air Pollution May Enhance COVID-19 Case-492 Fatality and Mortality Rates in the United States. *medRxiv*. 2020.
- 493 19. Wu X, Nethery R, Sabath M, Braun D, Dominici F. Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study.
 495 *medRxiv.* 2020.
- 496 20. Environmental racism: time to tackle social injustice. *The Lancet Planetary* 497 *Health.* 2018;2(11).
- 498 21. Niedzwiedz CL, O'Donnell CA, Jani BD, et al. Ethnic and socioeconomic 499 differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. 500 BMC Med. 2020;18(1):160.
- 501 22. Griffith G, Morris T, Tudball M, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *medRxiv*. 2020.
- 503 23. Hernán M, Robins J. Causal Inference. 2014.
- 504 24. Elwert F, Winship C. Endogenous Selection Bias: The Problem of Conditioning on a Collider Variable. *Annu Rev Sociol.* 2014;40:31-53.
- 506 25. Health care in Ontario: OHIP. https://www.ontario.ca/page/health-care-ontario. Published 2020. Accessed October 29, 2020.
- 508 26. Schedule of benefits for laboratory services. Ontario: Ministry of Health, Ontario Health Insurance Plan, Laboratories and Genetics Branch; July 1 2020.
- 510 27. IC/ES: Data, Discovery, Better Health. https://www.ices.on.ca. Published 2020. Accessed October 29, 2020.
- 512 28. Data products, 2016 Census. Statistics Canada/Statistique Canada.
- 513 https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/index-eng.cfm.
 514 Published 2020. Accessed October 29, 2020.
- 515 29. Pennington E. Asthma increases risk of severity of COVID-19. *Cleve Clin J Med.* 516 2020.
- 517 30. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. *Nature*. 2020.
- 519 31. Fang L, Karakiulakis G, Roth M. Are patients with hyperetension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respiratory Medicine*. 2020;8:e21.
- 522 32. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with COVID-19 versus patients with influenza. *medRxiv*. 2020.
- 524 33. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: May* 525 14, 2020. May 14 2020.
- 526 34. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: May 2, 2020.* May 2 2020.
- 528 35. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: April* 529 15, 2020. April 15 2020.

- 530 36. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: May* 531 28, 2020. May 28 2020.
- 532 37. Ontario Ministry of Health. COVID-19 Quick Reference Public Health Guidance on Testing and Clearance: March 27, 2020. 2020.
- 534 38. Ontario Ministry of Health. *COVID-19 Provincial Testing Guidance Update: April* 535 8, 2020. April 8, 2020 2020.
- Tolea MI, Morris JC, Galvin JE. Trajectory of Mobility Decline by Type of Dementia. *Alzheimer Dis Assoc Disord.* 2016;30(1):60-66.
- 538 40. Chiao C-Y, Wu H-S, Hsiao C-Y. Caregiver burden for informal caregivers of patients with dementia: A systematic review. *Int Nurs Rev.* 2015;62(3):340-350.
- 540 41. Johns Hopkins ACG(c) System. Johns Hopkins. https://www.hopkinsacg.org. Published 2020. Accessed November 1, 2020.
- 42. Austin PC, van Walraven C, Wodchis WP, Newman A, Anderson GM. Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. *Med Care*. 2011;49(10):932-939.
- van Donkelaar A, Martin RV, Brauer M, Boys BL. Use of Satellite Observations
 for Long-Term Exposure Assessment of Global Concentrations of Fine
 Particulate Matter. *Environ Health Perspect.* 2015;123:135-143.
- Hystad P, Setton E, Cervantes A, et al. Creating national air pollution models for population exposure assessment in Canada. *Environ Health Perspect*.
 2011;119(8):1123-1129.
- 552 45. Walker P, Whittaker C, Watson O, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science*. 554 2020;369(6502):413-422.
- 555 46. Park SY, Kim YM, Yi S, et al. Coronavirus Disease Outbreak in Call Center, South Korea. *Emerg Infect Dis.* 2020;26(8):1666-1670.
- 557 47. Karaye IM, Horney JA. The Impact of Social Vulnerability on COVID-19 in the U.S.: An Analysis of Spatially Varying Relationships. *American journal of preventive medicine*. 2020;59(3):317-325.
- 560 48. Rodriguez-Diaz CE, Guilamo-Ramos V, Mena L, et al. Risk for COVID-19 561 infection and death among Latinos in the United States: examining heterogeneity 562 in transmission dynamics. *Ann Epidemiol*. 2020.
- 563 49. Statistics Canada/Statistique Canada. Dictionary, Census of Population, 2016.
 564 https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/geo021-eng.cfm.
 565 Published 2020. Accessed October 13, 2020.
- 566 50. Public Health Units. https://www.ontario.ca/page/public-health-units. Published 2017. Updated March 22, 2019. Accessed October 29, 2020.
- 568 51. Enhanced epidemiological summary: COVID-19 in Ontario—a focus on diversity. Public Health Ontario;2020.
- 570
 52. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test 571 Negative Study Design for Assessment of Influenza Vaccine Effectiveness.
 572 American journal of epidemiology. 2016;184(5):345-353.
- 573 53. Lin SL. Intersectionality and inequalities in medical risk for severe COVID-19 in the Canadian Longitudinal Study on Aging. *Gerontologist.* 2020.

- 575 54. Drefahl S, Wallace M, Mussino E, et al. A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. *Nat Commun.* 2020;11(1):5097.
- 578 55. Workplace Safety & Prevention Services Guidance on Health and Safety for the
 579 Personal Care Service Sector during COVID-19. Ontario: Workplace Safety &
 580 Prevention Services;2020.
- 581 56. Dyal J, Grant M, Broadwater K, et al. COVID-19 among workers in meat and poultry processing facilities—19 states, April 2020. *Morbidity and Mortality Weekly Report.* 2020;69(18):557-561.
- 584 57. Contrera J. The N95 shortage America can't seem to fix. *Washington Post.* September 21, 2020, 2020.
- 586 58. Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and ethnic disparities in SARS-587 CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US 588 metropolitan population. *BMJ Open.* 2020;10(8):e039849.
- 59. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *The Lancet Infectious Diseases*. 2020;20(9):1034-1042.
- 593 60. Liem A, Wang C, Wariyanti Y, Latkin CA, Hall BJ. The neglected health of 594 international migrant workers in the COVID-19 epidemic. *The Lancet Psychiatry*. 595 2020;7(4).
- 596 61. Ordóñez CE. Not race, racism: Concerns of COVID-19 affecting African 597 Americans. *Anthropological Responses to Heatlh Emergencies*. 2020.
- 598 62. Dodds C, Fakoya I. Covid-19: ensuring equality of access to testing for ethnic minorities. *BMJ*. 2020;369:m2122.
- 600 63. Brandén M, Aradhya S, Kolk M, et al. Residential context and COVID-19
 601 mortality among adults aged 70 years and older in Stockholm: a population602 based, observational study using individual-level data. *The Lancet Healthy Longevity*. 2020.
- 604 64. Jordan-Martin NC, Madad S, Alves L, et al. Isolation Hotels: A Community-Based 605 Intervention to Mitigate the Spread of the COVID-19 Pandemic. *Health Secur.* 606 2020.
- 607 65. Vazquez J, Islam T, Beller J, et al. Expanding paid sick leave as a public health tool in the COVID-19 pandemic. *J Occup Environ Med.* 2020;Letter to the Editor.
- 609 66. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. *JAMA*. 2020.
- 611 67. Yang TC, Emily Choi SW, Sun F. COVID-19 cases in US counties: roles of racial/ethnic density and residential segregation. *Ethn Health*. 2020:1-11.
- 613 68. Wallis G, Siracusa F, Blank M, et al. Experience of a novel community testing programme for COVID-19 in London: Lessons learnt. *Clin Med (Lond)*. 2020;20(5):e165-e169.
- 616 69. ICES COVID-19 Dashboard. ICES. https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard. Published 2020. Accessed October 29, 2020.
- 70. Ontario COVID-19 Data Tool. Public Health Ontario.
- 619 https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/covid-

- 620 <u>19-data-surveillance/covid-19-data-tool</u>. Published 2020. Accessed October 29, 2020.
- 71. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol.* 2020;17(9):543-558.
- Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res Clin Pract.* 2020;162:108142.
- 627 73. Elliot AJ, Harcourt SE, Hughes HE, et al. The COVID-19 pandemic: a new challenge for syndromic surveillance. *Epidemiol Infect.* 2020;148:e122.
- 629 74. Morelli X, Rieux C, Cyrys J, Forsberg B, Slama R. Air pollution, health and social deprivation: A fine-scale risk assessment. *Environ Res.* 2016;147:59-70.
- 75. Næss Ø, Piro FN, Nafstad P, Smith GD, Leyland AH. Air Pollution, Social Deprivation, and Mortality. *Epidemiology*. 2007;18(6):686-694.
- 633 76. Wang L, Ma H, Yiu KCY, et al. Heterogeneity in risk, testing and outcome of COVID-19 across outbreak settings in the Greater Toronto Area, Canada: an observational study. *medRxiv*. 2020.
- 636 77. Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. *American journal of epidemiology*. 638 2013;177(4):292-298.
- 639 78. Kwok S, Adam S, Ho JH, et al. Obesity: A critical risk factor in the COVID-19 pandemic. *Clin Obes.* 2020:e12403.
- 79. ICES Data Dictionary. ICES.

- 642 https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx.
 643 Published 2020. Accessed November 1, 2020.
- 80. In: NAAQS Table, ed. Washington, DC: United States Environmental Protection Agency.

Table 1. Characteristics of study population tested and not tested for SARS-CoV-2 in Ontario (March 1, 2020 to

June 20, 2020).

Julie 20, 2020).	Tested individuals		Symptomatic test only	ed individuals	All individuals	
	Tested negative (N = 733,661)	Tested positive (N = 25,030)	Tested negative and symptomatic (N = 85,355)	Tested positive and symptomatic (N = 4,053)	Untested control group (N = 13,936,888)	All tested (N =758,691)
Demographic characteristics						
Age: mean (SD)	49.52 ± 20.99	47.45 ± 19.77	47.91 ± 20.80	50.83 ± 20.39	40.31 ± 22.91	49.45 ± 20.95
Age groups (years)						
0-4	10,870 (1.5%)	223 (0.9%)	1,627 (1.9%)	17 (0.4%)	727,305 (5.2%)	11,093 (1.5%) 34.791 (4.6%)
5-19	33,642 (4.6%)	1,149 (4.6%)	4,017 (4.7%)	125 (3.1%)	2,395,518 (17.2%)	34,791 (4.6%)
20-34	157,086 (21.4%)	6,015 (24.0%)	19,431 (22.8%)	864 (21.3%)	2,810,230 (20.2%)	163,101 (21.5%)
35-49	160,506 (21.9%)	6,084 (24.3%)	20,495 (24.0%)	934 (23.0%)	2,772,204 (19.9%)	166,590 (22.0%)
50-64	192,178 (26.2%)	7,009 (28.0%)	21,329 (25.0%)	1,159 (28.6%)	2,865,926 (20.6%)	199,187 (26.3%)
65-74	84,077 (11.5%)	2,072 (8.3%)	8,765 (10.3%)	386 (9.5%)	1,394,043 (10.0%)	86,149 (11.4%)
75-84	52,655 (7.2%)	1,284 (5.1%)	5,181 (6.1%)	251 (6.2%)	713,639 (5.1%)	53,939 (7.1%)
≥85	42,647 (5.8%)	1,194 (4.8%)	4,510 (5.3%)	317 (7.8%)	258,023 (1.9%)	43,841 (5.8%)
Male sex: N (%)	289,769 (39.5%)	11,627 (46.5%)	33,078 (38.8%)	1,898 (46.8%)	6,930,233 (49.7%)	301,396 (39.7%)
Living in rural/small town: N (%) ^a	82,034 (11.2%)	887 (3.5%)	14,140 (16.6%)	304 (7.5%)	1,390,426 (10.0%)	82,921 (10.9%)
Public Health region						
Central East	59,951 (8.2%)	707 (2.8%)	7,898 (9.3%)	193 (4.8%)	874,010 (6.3%)	60,658 (8.0%)
Central West	136,116 (18.6%)	3,375 (13.5%)	17,469 (20.5%)	951 (23.5%)	2,683,999 (19.3%)	60,658 (8.0%) 139,491 (18.4%) 31,862 (4.2%) 53,563 (7.1%)
Durham	30,618 (4.2%)	1,244 (5.0%)	1,341 (1.6%)	125 (3.1%)	671,605 (4.8%)	31,862 (4.2%)
Eastern	53,097 (7.2%)	466 (1.9%)	9,752 (11.4%)	152 (3.8%)	829,504 (6.0%)	53,563 (7.1%)
North	56,977 (7.8%)	308 (1.2%)	14,442 (16.9%)	177 (4.4%)	761,495 (5.5%)	57,285 (7.6%)
Ottawa	52,754 (7.2%)	1,360 (5.4%)	3,761 (4.4%)	190 (4.7%)	980,501 (7.0%)	54,114 (7.1%)
Peel	63,093 (8.6%)	4,464 (17.8%)	5,780 (6.8%)	376 (9.3%)	1,465,044 (10.5%)	67,557 (8.9%)
South West	87,412 (11.9%)	2,040 (8.2%)	9,101 (10.7%)	673 (16.6%)	1,609,925 (11.6%)	89,452 (11.8%)
Toronto	140,217 (19.1%)	8,728 (34.9%)	10,360 (12.1%)	797 (19.7%)	2,761,786 (19.8%)	148,945 (19.6%)
York	48,565 (6.6%)	2,119 (8.5%)	5,068 (5.9%)	376 (9.3%)	1,157,124 (8.3%)	50,684 (6.7%)
Underlying chronic health						
conditions						
Asthma	136,556 (18.6%)	3,887 (15.5%)	17,831 (20.9%)	671 (16.6%)	2,085,118 (15.0%)	140,443 (18.5%)
COPD	34,261 (4.7%)	715 (2.9%)	4,616 (5.4%)	168 (4.1%)	249,636 (1.8%)	34,976 (4.6%)

Dilabetes	Hypertension	226,111 (30.8%)	7,488 (29.9%)	24,364 (28.5%)	1,313 (32.4%)	2,836,790 (20.4%)	233,599 (30.8%)
Congestive heart failure 35,947 (4.9%) 983 (3.9%) 3.864 (4.5%) 194 (4.8%) 225,153 (1.6%) 36,930 (4.9%) Dementia or frailty 31,804 (4.3%) 1.106 (4.4%) 3.399 (4.0%) 267,33% 124,295 (0.9%) 32,910 (4.3%) 24,333 (3.3%) 484 (1.9%) 2.333 (2.7%) 89 (2.2%) 213,036 (1.5%) 24,817 (3.3%)							
Dementia or fraility 31,804 (4.3%) 1,106 (4.4%) 3,399 (4.0%) 296 (7.3%) 124,295 (0.9%) 32,910 (4.3%) Cancer 24,333 (3.3%) 484 (1.9%) 2,333 (2.7%) 89 (2.2%) 213,036 (1.5%) 24,817 (3.3%) Chronic kidney disease* 37,630 (5.1%) 1,122 (4.5%) 3,581 (4.2%) 199 (4.9%) 254,541 (1.8%) 38,752 (5.1%) Immunocompromised* 13,325 (1.8%) 319 (1.3%) 1,486 (1.8%) 57 (1.4%) 107,824 (0.8%) 13,644 (1.8%) 84,747 (0.6%) 9,232 (1.2%) 120,88% 1,045 (1.2%) 35 (0.9%) 78,747 (0.6%) 9,232 (1.2%) 18chemic kidney disease 9,020 (1.2%) 212 (0.8%) 1,045 (1.2%) 35 (0.9%) 78,747 (0.6%) 9,232 (1.2%) 18chemic kidney disease 33,855 (4.6%) 880 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 18chemic kidney disease 13,855 (4.6%) 880 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 18chemic kidney disease 13,855 (4.6%) 180 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 18chemic kidney disease 13,855 (4.6%) 180 (3.5%) 1,531 (1.8%) 77 (1.9%) 99,503 (0.7%) 14,188 (1.9%) 150 (1.5%) 150 (1.5%) 150 (1.5%) 160 (. ,	,			,	. ,
Cancer ¹ Chronic kidney disease ¹⁰ 37,630 (5.1%) 1,122 (4.5%) 3,581 (4.2%) 199 (4.9%) 254,541 (1.8%) 38,752 (5.1%) Immunocompromised ² 13,325 (1.8%) 319 (1.3%) 1,496 (1.8%) 57 (1.4%) 107,824 (0.8%) 13,644 (1.8%) Advanced liver disease 9,020 (1.2%) 212 (0.8%) 1,496 (1.8%) 35 (0.9%) 77,14%; 107,824 (0.8%) 13,644 (1.8%) 88,03.5% (1.4%) 188 (1.1%) 324,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 3,773 (4.4%) 188 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 3,773 (4.4%) 188 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 3,773 (4.4%) 188 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 3,773 (4.4%) 188 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 3,773 (4.4%) 188 (4.1%) 324,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 37,736 (4.6%) 18,777 (1.9%) 99,503 (0.7%) 14,188 (1.9%) 7,746 (1.0%) 524,682 (2.3%) 34,735 (4.6%) 880 (3.5%) 732 (0.9%) 42 (1.0%) 64,494 (0.5%) 7,746 (1.0%) 524,682 (2.3%) 34,736 (4.6%) 18,181 (2.2%) 19		. ,				. ,	, ,
Chronic kidney disease* 37,630 (5.1%) 1,122 (4.5%) 3,581 (4.2%) 199 (4.9%) 254,541 (1.8%) 38,752 (5.1%) Immunocompromised* 13,325 (1.8%) 319 (1.3%) 1,496 (1.8%) 57 (1.4%) 107,824 (0.8%) 13,644 (1.8%) Advanced liver disease 3,855 (4.6%) 880 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) Ischemic heart disease 3,855 (4.6%) 880 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) Ischemic heart disease 13,777 (1.9%) 411 (1.6%) 1,531 (1.8%) 7,19%) 99,503 (0.7%) 14,188 (1.9%) Schizophrenia* 7,526 (1.0%) 220 (0.9%) 732 (0.9%) 42 (1.0%) 64,494 (0.5%) 7,746 (1.0%) Substance abuse* 22,238 (3.0%) 478 (1.9%) 3,001 (3.5%) 59 (1.5%) 216,156 (1.6%) 22,716 (3.0%) Healthcare use Adjusted Diagnostic Group quintile 1 (0.ADGs) 31,959 (4.4%) 1,571 (6.3%) 3,006 (3.5%) 247 (6.1%) 1,616,852 (11.6%) 33,530 (4.4%) 2 (1-2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 595 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 4 (5-6 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,220 (20.2%) 78,193% 3,385,602 (24.3%) 154,274 (20.3%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) Hospital admissions, past 3 years: Mean (SD) 0,44 ± 1.34 0,33 ± 1.21 0,45 ± 1.29 0,36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.04 ± 1.34 0.35 ± 8.68 7.06 ± 8.33 7.15 ± 8.40 7.07 ± 8.64 4.67 ± 6.05 7.34 ± 8.67 (SD) Influenza vaccination (2019-2020 season) 213,722 (29.1%) 5,547 (22.2%) 23,429 (27.4%) 1,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 210 -60 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) PM ₂₅₂ category (µg/m³ yearly) 210 -60 1,747 (7.0%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,74					` ,	. ,	, ,
Immunocompromised* 13,325 (1.8%) 319 (1.3%) 1,496 (1.8%) 57 (1.4%) 107,824 (0.8%) 13,644 (1.8%) Advanced liver disease 9,020 (1.2%) 212 (0.8%) 1,045 (1.2%) 35 (0.9%) 78,747 (0.6%) 9,232 (1.2%) 1,045 (1.2%) 35 (0.9%) 78,747 (0.6%) 9,232 (1.2%) 1,045 (1.2%) 35 (0.9%) 78,747 (0.6%) 9,232 (1.2%) 1,045 (1.2%) 35 (0.9%) 324,682 (2.3%) 34,735 (4.6%) 1,045 (1.2%) 1,045 (1.2%) 324,682 (2.3%) 34,735 (4.6%) 1,045 (1.2%) 1,045 (1.1%) 1,045 (1.		. ,	` ,	,		. ,	. ,
Advanced liver disease 9,020 (1,2%) 212 (0.8%) 1,045 (1,2%) 35 (0.9%) 78,747 (0.6%) 9,232 (1,2%) Ischemic heart disease 33,855 (4.6%) 880 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) Ischemic stroke or TIA* 13,777 (1.9%) 411 (1.6%) 1,531 (1.8%) 77 (1.9%) 99,503 (0.7%) 14,188 (1.9%) Schizophrenia* 7,526 (1.0%) 220 (0.9%) 732 (0.9%) 42 (1.0%) 64,494 (0.5%) 7,746 (1.0%) Substance abuse* 22,238 (3.0%) 478 (1.9%) 3,001 (3.5%) 59 (1.5%) 216,156 (1.6%) 22,716 (3.0%) Healthcare use Adjusted Diagnostic Group quintile 1 (0.ADCs) 31,959 (4.4%) 1,571 (6.3%) 3,006 (3.5%) 247 (6.1%) 3,150,969 (22.6%) 105,496 (13.9%) 3 (3.4 ADGs) 149,173 (20.3%) 5,101 (20.4%) 17,220 (20.2%) 782 (19.3%) 3,385,602 (24.3%) 154,274 (20.3%) 4 (5-6 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 15 (7.27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 30,982 (40.8%) 10,044 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.32 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.31 (1.25%) 0.20 ± 1.25 (1.25%) 0.20 ± 1.25 (1.25%) 0.20 ± 1.25 (1.25%) 0.20 ± 1.25 (1.25%) 0.20 ± 1.25 (1.25%) 0.20 ± 1.25 (1.25%)		. ,	. ,	,	` ,	. ,	. ,
Ischemic heart disease 33,855 (4.6%) 880 (3.5%) 3,773 (4.4%) 168 (4.1%) 324,682 (2.3%) 34,735 (4.6%) Schizophrenia* 7,526 (1.0%) 411 (1.6%) 1,531 (1.8%) 77 (1.9%) 99,503 (0.7%) 14,188 (1.9%) 732 (0.9%) 42 (1.0%) 64,494 (0.5%) 7,746 (1.0%)		. ,	` ,	, , ,	` ,	. ,	. ,
Ischemic stroke or TIA ³							
Schizophrenia ⁶ 7,526 (1.0%) 220 (0.9%) 732 (0.9%) 42 (1.0%) 64,494 (0.5%) 7,746 (1.0%) Substance abuse ⁶ 22,238 (3.0%) 478 (1.9%) 3,001 (3.5%) 59 (1.5%) 216,156 (1.6%) 22,716 (3.0%) Healthcare use Adjusted Diagnostic Group quintile 1 (0 ADGs) 31,959 (4.4%) 1,571 (6.3%) 3,006 (3.5%) 247 (6.1%) 1,616,852 (11.6%) 33,530 (4.4%) 2 (1.2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 595 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 4 (5.6 ADGs) 150,394 (20.5%) 5,101 (20.4%) 17,220 (20.2%) 782 (19.3%) 3,385,602 (24.3%) 154,274 (20.3%) 5 (7.27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) 100,44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.33 ± 0.20 (20.2%) 7.34 ± 8.67 (SD) 1nfluenza vaccination (2019-2020 season) 213,722 (29.1%) 5,547 (22.2%) 23,429 (27.4%) 1,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) Environmental determinants (2019-2020 season) 213,722 (29.1%) 1,666 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <6 16.37 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 29 59,674 (8.1%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO ₂ category (parts per billion yearly)							
Substance abuse® 22,238 (3.0%) 478 (1.9%) 3,001 (3.5%) 59 (1.5%) 216,156 (1.6%) 22,716 (3.0%)							
Healthcare use Adjusted Diagnostic Group quintile 1 (0 ADGs) 31,959 (4.4%) 1,571 (6.3%) 3,006 (3.5%) 247 (6.1%) 1,616,852 (11.6%) 33,530 (4.4%) 2 (1-2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 555 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 4 (5-6 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,736 (20.8%) 8 22 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) Hospital admissions, past 3 years: Mean (SD) Outpatient physician visits, past year: Mean (SD) Influenza vaccination (2019-2020 season) Environmental determinants' PM _{2.5} category (µg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 8 to <9 211,861 (28.9%) 1,1127 (44.5%) 1,639 (23.0%) 1,747 (7.0%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,749 (6.7%) 5,747 (12.8%) 1,073,665 (7.7%) 6,1,421 (8.1%) 1,073,665 (7.7%) 6,1,421 (8.1%) 1,073,665 (7.7%) 6,1,421 (8.1%) 1,073,665 (7.7%) 6,1,421 (8.1%) 1,073,665 (7.7%) 6,1,421 (8.1%)							
Adjusted Diagnostic Group quintile Adjusted Diagnostic Group quintile 1.571 (6.3%) 3.006 (3.5%) 247 (6.1%) 1.616,852 (11.6%) 33,530 (4.4%) 1 (0 ADGs) 31,959 (4.4%) 1,571 (6.3%) 3.006 (3.5%) 247 (6.1%) 1.616,852 (11.6%) 33,530 (4.4%) 2 (1-2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 595 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 3 (3-4 ADGs) 149,173 (20.3%) 5,101 (20.4%) 17,220 (20.2%) 782 (19.3%) 3,385,602 (24.3%) 154,274 (20.3%) 4 (5-6 ADGs) 150,394 (20.5%) 5,111 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) Hospital admissions, past 3 years: Mean (SD) 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 Outpatient physician visits, past year: Mean (SD) 7.35 ± 8.68 7.06 ± 8.33 7.15 ± 8.40 7.07 ± 8.64 4.67 ± 6.05 7.34 ± 8.67 Environmental determinants		22,238 (3.0%)	478 (1.9%)	3,001 (3.5%)	59 (1.5%)	210,150 (1.0%)	22,716 (3.0%)
Group quintile 1 (0 ADGs) 31,959 (4.4%) 1,571 (6.3%) 3,006 (3.5%) 247 (6.1%) 1,616,852 (11.6%) 33,530 (4.4%) 2 (1-2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 595 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 4 6.6 ADGs) 149,173 (20.3%) 5,101 (20.4%) 17,220 (20.2%) 782 (19.3%) 3,385,602 (24.3%) 154,274 (20.3%) 6 4 (5-6 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) 155,509 (20.5%) 309,882 (40.8%) 3,157,062 (22.7%) 309,882 (40.8%) 30,9882 (40.8%) 4,67 ± 6.05 7,34 ± 8.67 309,882 (40.8%) 4,467 ± 6.05 7,34 ± 8.67 3,157,062 (22.7%) 309,882 (40.8%) 4,467 ± 6.05 7,34 ± 8.67 3,157,062 (22.7%) 309,882 (40.8%) 4,467 ± 6.05 7,34 ± 8.67 3,157,062 (22.7%) 309,882 (40.8%) 4,467 ± 6.05 7,34 ± 8.67 3,157,062 (22.7%) 3,157,062 (22.7%) 3,157,062 (22.7%) 3,157							q
1 (0 ÅDGs) 31,959 (4.4%) 1,571 (6.3%) 3,006 (3.5%) 247 (6.1%) 1,616,852 (11.6%) 33,530 (4.4%) 2 (1-2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 595 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 4 (5-6 ADGs) 150,394 (20.5%) 5,101 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) 149,173 (20.3%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) 150,394 (20.5%) 1,355,982 (39.5%) 1,355,982 (39.5%) 1,355,982 (39.5%) 1,355,982 (39.5%) 1,355,982 (39.5%) 1,355,982 (39.5%) 1,355,982 (39.5%) 1,355,992 (11.2%) 1,019 (25.1	,						
2 (1-2 ADGs) 101,895 (13.9%) 3,601 (14.4%) 11,419 (13.4%) 595 (14.7%) 3,150,969 (22.6%) 105,496 (13.9%) 3 (3-4 ADGs) 149,173 (20.3%) 5,101 (20.4%) 17,220 (20.2%) 782 (19.3%) 3,385,602 (24.3%) 154,274 (20.3%) 5 (7-27 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) 159,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) 10,44 ± 1.34		04.050 (4.40()	4 574 (0.00()	0.000 (0.50()	0.47 (0.40()	4 040 050 (44 00/)	00 500 (4 40()
3 (3-4 ADGs) 149,173 (20.3%) 5,101 (20.4%) 17,220 (20.2%) 782 (19.3%) 3,385,602 (24.3%) 154,274 (20.3%) 4 (5-6 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) Hospital admissions, past 3 years: Mean (SD) 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.45 ± 1.29 0.36 ± 1.09 0.44 ± 1.34 0.45 ± 1.29 0.45	,	, ,	, ,	, , ,	,	,	. ,
4 (5-6 ADGs) 150,394 (20.5%) 5,115 (20.4%) 17,736 (20.8%) 822 (20.3%) 2,626,403 (18.8%) 155,509 (20.5%) 5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) Hospital admissions, past 3 years: Mean (SD) Outpatient physician visits, past year: Mean (SD) Influenza vaccination (2019-2020 season) Environmental determinants¹ PM _{2.5} category (μg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) 6 to <7 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 8 to <9 211,861 (28.9%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO ₂ category (parts per billion yearly)	,	. ,		,	` '	,	` , ,
5 (7-27 ADGs) 300,240 (40.9%) 9,642 (38.5%) 35,974 (42.1%) 1,607 (39.6%) 3,157,062 (22.7%) 309,882 (40.8%) Hospital admissions, past 3 years: Mean (SD) 0.44 ± 1.34 0.33 ± 1.21 0.45 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 Outpatient physician visits, past year: Mean (SD) 7.35 ± 8.68 7.06 ± 8.33 7.15 ± 8.40 7.07 ± 8.64 4.67 ± 6.05 7.34 ± 8.67 (SD) Influenza vaccination (2019-2020 season) 213,722 (29.1%) 5,547 (22.2%) 23,429 (27.4%) 1,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) Environmental determinants ^f PM _{2.5} category (µg/m³ yearly) 2 20 < 6							
Hospital admissions, past 3 years: Mean (SD) Outpatient physician visits, past year: Mean (SD) Influenza vaccination (2019-2020 season) Environmental determinants PM2.s category (μg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 2 to <8 207,966 (28.3%) 3 to <8 207,966 (28.3%) 3 to <9 211,861 (28.9%) 1,045 ± 1.29 0.36 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.49 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.46 ± 1.09 0.49 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.49 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.19 ± 0.60 0.44 ± 1.34 0.46 ± 1.09 0.46 ± 1.09 0.49 ± 1.09 0.46 ± 1							155,509 (20.5%)
3 years: Mean (SD) Outpatient physician visits, past year: Mean (SD) Influenza vaccination (2019-2020 season) Environmental determinants¹ PM _{2.5} category (μg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 6 to <7 91,134 (12.4%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 2 to <8 207,966 (28.3%) 8 to <9 211,861 (28.9%) NO₂ category (μg/m² yearly) 2 to <6 11,861 (28.9%) 1,747 (7.0%) 1,747 (7.0%) 1,749 (6.7%) 1,749 (6.7%) 1,019 (25.1%) 1,019 (25.1%) 1,019 (25.1%) 1,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,9269 (28.9%) 21,9269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4%) 21,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) 21,019 (25.1%) 2,978,472 (21.4		300,240 (40.9%)	9,642 (38.5%)	35,974 (42.1%)	1,607 (39.6%)	3,157,062 (22.7%)	309,882 (40.8%)
Outpatient physician visits, past year: Mean (SD) Influenza vaccination (2019-2020 season) Environmental determinants' PM _{2.5} category (μg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) 6 to <7 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 8 to <9 211,861 (28.9%) 11,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO₂ category (parts per billion yearly)		0.44 ± 1.34	0.33 ± 1.21	0.45 ± 1.29	0.36 ± 1.09	0.19 ± 0.60	0.44 + 1.34
visits, past year: Mean (SD) 7.35 ± 8.68 7.06 ± 8.33 7.15 ± 8.40 7.07 ± 8.64 4.67 ± 6.05 7.34 ± 8.67 (SD) 7.07 ± 8.64 4.67 ± 6.05 7.34 ± 8.67 7.34 ± 8.67 (SD) 7.35 ± 8.68 7.06 ± 8.33 7.15 ± 8.40 7.07 ± 8.64 4.67 ± 6.05 7.34 ± 8.67 1.34 ± 8.67 1.34 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ± 8.42 ± 8.67 ± 8.42 ± 8.42 ± 8.67 ± 8.42 ± 8.67 ± 8.42 ±			0.00	01.10 2 1.120	0.00 = 1.00	0.10 = 0.00	011121101
(SD) Influenza vaccination (2019-2020 season) Environmental determinants							
Influenza vaccination (2019-2020 season) 213,722 (29.1%) 5,547 (22.2%) 23,429 (27.4%) 1,019 (25.1%) 2,978,472 (21.4%) 219,269 (28.9%) Environmental determinants ^f PM _{2.5} category (µg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) 6 to <7		7.35 ± 8.68	7.06 ± 8.33	7.15 ± 8.40	7.07 ± 8.64	4.67 ± 6.05	7.34 ± 8.67
Collection Co							-
Environmental determinants ¹ PM _{2.5} category (μg/m³ yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) 6 to <7 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 8 to <9 211,861 (28.9%) 11,127 (44.5%) 19,639 (23.0%) 1,363 (33.6%) 4,258,069 (30.6%) 222,988 (29.4%) ≥9 59,674 (8.1%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO₂ category (parts per billion yearly)		213.722 (29.1%)	5.547 (22.2%)	23.429 (27.4%)	1.019 (25.1%)	2.978.472 (21.4%)	219.269 (28.9%)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		-, (,	-,- (,	-, - (,	, (77 (7	-, (
PM _{2.5} category (μg/m³ yearly) 2 to <6							
yearly) 2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) 5 to <7 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 8 to <9 211,861 (28.9%) 11,127 (44.5%) 19,639 (23.0%) 1,363 (33.6%) 4,258,069 (30.6%) 222,988 (29.4%) NO₂ category (parts per billion yearly) NO₂ category (parts per billion yearly)							
2 to <6 161,300 (22.0%) 1,831 (7.3%) 27,764 (32.5%) 556 (13.7%) 2,481,201 (17.8%) 163,131 (21.5%) 6 to <7 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 29 59,674 (8.1%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO₂ category (parts per billion yearly)							
6 to <7 91,134 (12.4%) 1,766 (7.1%) 10,930 (12.8%) 318 (7.8%) 1,555,790 (11.2%) 92,900 (12.2%) 7 to <8 207,966 (28.3%) 8,476 (33.9%) 21,183 (24.8%) 1,281 (31.6%) 4,450,218 (31.9%) 216,442 (28.5%) 8 to <9 211,861 (28.9%) 11,127 (44.5%) 19,639 (23.0%) 1,363 (33.6%) 4,258,069 (30.6%) 222,988 (29.4%) ≥9 59,674 (8.1%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO₂ category (parts per billion yearly)		404 000 (00 00)	4 004 (7 004)	07.704/00.70()	FEO (40 TO()	0.404.004.(47.00()	400 404 (04 704)
7 to <8							
8 to <9 211,861 (28.9%) 11,127 (44.5%) 19,639 (23.0%) 1,363 (33.6%) 4,258,069 (30.6%) 222,988 (29.4%) ≥9 59,674 (8.1%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO₂ category (parts per billion yearly)			, ,			,	
≥9 59,674 (8.1%) 1,747 (7.0%) 5,749 (6.7%) 517 (12.8%) 1,073,665 (7.7%) 61,421 (8.1%) NO₂ category (parts per billion yearly)							
NO ₂ category (parts per billion yearly)		. ,			. ,		. ,
billion yearly)		59,674 (8.1%)	1,747 (7.0%)	5,749 (6.7%)	517 (12.8%)	1,073,665 (7.7%)	61,421 (8.1%)
	0 to 6	328,613 (44.8%)	5,237 (20.9%)	48,579 (56.9%)	1,500 (37.0%)	5,505,976 (39.5%)	333,850 (44.0%)

6 to 8	170,693 (23.3%)	5,599 (22.4%)	17,477 (20.5%)	1,079 (26.6%)	3,409,506 (24.5%)	176,292 (23.2%)
≥8	232,629 (31.7%)	14,111 (56.4%)	19,209 (22.5%)	1,456 (35.9%)	4,903,460 (35.2%)	246,740 (32.5%)
Social determinants of		,	,	, ,	, ,	, ,
health ^g (area-level)						
Household income						
quintile ^h						
1 (lowest income)	156,320 (21.3%)	7,000 (28.0%)	17,159 (20.1%)	857 (21.1%)	2,679,780 (19.2%)	163,320 (21.5%)
2	148,687 (20.3%)	5,288 (21.1%)	17,057 (20.0%)	757 (18.7%)	2,698,807 (19.4%)	153,975 (20.3%)
3	145,317 (19.8%)	5,084 (20.3%)	16,771 (19.6%)	756 (18.7%)	2,791,340 (20.0%)	150,401 (19.8%)
4	140,352 (19.1%)	4,019 (16.1%)	17,162 (20.1%)	730 (18.0%)	2,809,529 (20.2%)	144,371 (19.0%)
5 (highest income)	138,103 (18.8%)	3,419 (13.7%)	16,822 (19.7%)	910 (22.5%)	2,815,238 (20.2%)	141,522 (18.7%)
Social assistance						
quintile (percentage of						
individuals in the area						5
receiving governmental						
transfer payments)	111 110 (10 00()	0.000 (4.7.00())	45 504 (40 504)	704 (40 00()	0.040.045 (04.00()	144,975 (19.1%) 150,565 (19.8%) 142,195 (18.7%) 141,375 (18.6%) 166,611 (22.0%)
1 (38.0 - 63.5%)	141,146 (19.2%)	3,829 (15.3%)	15,784 (18.5%)	764 (18.9%)	3,016,045 (21.6%)	144,975 (19.1%)
2 (63.5 - 67.2%)	145,846 (19.9%)	4,719 (18.9%)	16,188 (19.0%)	794 (19.6%)	3,004,958 (21.6%)	150,565 (19.8%)
3 (67.2 - 70.8%)	137,208 (18.7%)	4,987 (19.9%)	16,155 (18.9%)	851 (21.0%)	2,658,737 (19.1%)	142,195 (18.7%)
4 (70.8 - 75.3%)	136,423 (18.6%)	4,952 (19.8%)	16,691 (19.6%)	736 (18.2%)	2,433,304 (17.5%)	141,375 (18.6%)
5 (75.3 - 98.1%)	160,519 (21.9%)	6,092 (24.3%)	19,144 (22.4%)	822 (20.3%)	2,571,707 (18.5%)	166,611 (22.0%)
Limited educational						
attainment quintile						
(percentage of adults						Į į
aged 25-64 in the area						
not having received any diploma)						
1 (0.0 - 4.1%)	144,457 (19.7%)	3,903 (15.6%)	15,245 (17.9%)	709 (17.5%)	2,926,432 (21.0%)	148,360 (19.6%)
2 (4.1 - 7.5%)	154,215 (21.0%)	4,477 (17.9%)	17,690 (20.7%)	869 (21.4%)	2,978,444 (21.4%)	158,692 (20.9%)
3 (7.5 - 11.4%)	151,457 (20.6%)	5,052 (20.2%)	17,765 (20.8%)	759 (18.7%)	2,888,525 (20.7%)	156,509 (20.6%)
4 (11.4 - 17.1%)	148,159 (20.2%)	5,314 (21.2%)	18,014 (21.1%)	847 (20.9%)	2,659,544 (19.1%)	153,473 (20.2%)
5 (17.1 - 94.3%)	129,580 (17.7%)	6,010 (24.0%)	16,160 (18.9%)	824 (20.3%)	2,333,134 (16.7%)	135,590 (17.9%)
Uncoupled quintile	129,360 (17.776)	0,010 (24.076)	10,100 (10.976)	024 (20.370)	2,333,134 (10.770)	133,390 (17.976)
(percent of individuals)						
1 (11.2 - 33.7%)	150,044 (20.5%)	3,539 (14.1%)	20,243 (23.7%)	824 (20.3%)	3,130,907 (22.5%)	153,583 (20.2%)
2 (33.7 - 38.4%)	128,561 (17.5%)	3,915 (15.6%)	15,262 (17.9%)	779 (19.2%)	2,698,847 (19.4%)	132,476 (17.5%)
3 (38.5 - 43.6%)	127,689 (17.4%)	4,632 (18.5%)	14,539 (17.0%)	693 (17.1%)	2,579,005 (18.5%)	132,321 (17.4%)
4 (43.6 - 51.0%)	145,560 (19.8%)	5,591 (22.3%)	15,894 (18.6%)	713 (17.6%)	2,633,710 (18.9%)	151,151 (19.9%)
5 (51.0 - 94.6%)	174,985 (23.9%)	7,037 (28.1%)	18,781 (22.0%)	976 (24.1%)	2,732,838 (19.6%)	182,022 (24.0%)
3 (31.0 - 34.070)	177,300 (20.370)	1,001 (20.1/0)	10,701 (22.070)	310 (24.170)	2,132,030 (13.070)	102,022 (24.070)

Hausahald danaitu						
Household density						
quintile (range of						
persons per dwelling)	400 000 (00 00()	0.000 (4.4.50()	00.000 (00.50()	070 (40 00()	0.474.004.(47.00()	100 000 (01 00()
1 (0 – 2.1)	162,623 (22.2%)	3,639 (14.5%)	20,066 (23.5%)	672 (16.6%)	2,474,391 (17.8%)	166,262 (21.9%)
2 (2.2 - 2.4)	140,653 (19.2%)	3,104 (12.4%)	19,406 (22.7%)	662 (16.3%)	2,368,013 (17.0%)	143,757 (18.9%)
3 (2.5 - 2.6)	104,896 (14.3%)	2,721 (10.9%)	13,059 (15.3%)	531 (13.1%)	1,866,317 (13.4%)	107,617 (14.2%)
4 (2.7 - 3)	166,089 (22.6%)	6,321 (25.3%)	17,843 (20.9%)	1,096 (27.0%)	3,291,097 (23.6%)	172,410 (22.7%)
5 (3.1 - 5.7)	152,578 (20.8%)	8,929 (35.7%)	14,345 (16.8%)	1,024 (25.3%)	3,775,489 (27.1%)	161,507 (21.3%)
Apartment building						
density category						
(percent of buildings						
that are apartment						
buildings in the area ^{i,j}						d
1 (0 – 7.3%)	391,477 (53.4%)	12,377 (49.4%)	46,693 (54.7%)	2,243 (55.3%)	7,994,323 (57.4%)	403,854 (53.2%)
2 (7.4 - 37.7%)	145,108 (19.8%)	3,874 (15.5%)	19,348 (22.7%)	739 (18.2%)	2,478,855 (17.8%)	148,982 (19.6%)
3 (37.7 - 104%)	190,244 (25.9%)	8,463 (33.8%)	18,678 (21.9%)	1,003 (24.7%)	3,301,839 (23.7%)	198,707 (26.2%)
Recent immigration						
category (percentage of						
individuals in the area						
who are recent						
immigrants ^k						
1 (0.0 - 2.1%)	401,300 (54.7%)	8,271 (33.0%)	54,845 (64.3%)	2,002 (49.4%)	6,967,468 (50.0%)	409,571 (54.0%)
2 (2.1 - 4.7%	146,772 (20.0%)	5,409 (21.6%)	14,834 (17.4%)	852 (21.0%)	2,858,064 (20.5%)	152,181 (20.1%)
3 (4.7 - 41.2%)	174,829 (23.8%)	11,018 (44.0%)	14,393 (16.9%)	1,133 (28.0%)	3,898,463 (28.0%)	185,847 (24.5%)
Visible minority quintile						
(percentage of						
individuals in the area						
self-identifying as a						
visible minority)						;
1 (0.0 - 2.2%)	130,912 (17.8%)	1,716 (6.9%)	21,800 (25.5%)	555 (13.7%)	2,115,641 (15.2%)	132,628 (17.5%)
2 (2.2 - 7.5%)	137,826 (18.8%)	2,233 (8.9%)	19,869 (23.3%)	677 (16.7%)	2,255,245 (16.2%)	140,059 (18.5%)
3 (7.5 - 18.7%)	137,744 (18.8%)	3,201 (12.8%)	16,345 (19.1%)	792 (19.5%)	2,451,335 (17.6%)	140,945 (18.6%)
4 (18.7 - 43.5%)	153,503 (20.9%)	5,466 (21.8%)	13,581 (15.9%)	887 (21.9%)	3,023,752 (21.7%)	158,969 (21.0%)
5 (43.5 - 102%) ¹	167,893 (22.9%)	12,140 (48.5%)	13,280 (15.6%)	1,097 (27.1%)	3,940,245 (28.3%)	180,033 (23.7%)
3 "- "						

^a "Rural" defined as located outside the commuting zone of a city with greater than 10,000 population. ^b Participants were counted if they had a diagnosis in the last 5 years.

^c Participants considered "immunocompromised" if they were HIV positive, or had an organ or bone marrow transplant, or another immunodeficient condition.

⁹ All variables in this category are area-level variables at the level of the Census Dissemination Area (DA).

^d This category includes individuals with ischemic stroke or TIA in the last 20 years.

^e This category includes individuals with a diagnosis in the last 2 years.

 $^{^{}f}$ Values of PM_{2.5} > 12µg/m³ or NO₂ > 53ppb yearly has been found to be associated with increased risk of other respiratory illnesses. 80 PM_{2.5} and NO₂ values are provided at the postal code, not DA, level.

^h Income quintile has variable cut-off values in each city or census area, to take cost of living into account. A DA being in quintile 1 means it is among the lowest 20% DAs in its city by income.

The census counts for apartment buildings are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

^j 7.3% represents the 60th percentile.

^k 2.1% represents the 60th percentile.

Census counts for individuals are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

Table 2. Odds of ever being tested for SARS-CoV-2 and of COVID-19 diagnosis in fully-adjusted analyses, using three analytic approaches, in Ontario, Canada between March 1 and June 20, 2020.

	Tested for SARS- CoV-2		Diagnosed with COVID-19		
Determinants	Tested vs. not tested aOR (95% CI)	Test-positive vs. test- negative among all individuals tested (Pseudo-test- negative design) aOR (95% CI)	Test-positive vs. test- negative among symptomatic individuals only (True test-negative design) aOR (95% CI)	Test-positive vs. not test-positive (i.e., all negatives and all untested individuals) (Case-control design) aOR (95% CI) ^a	
Sample size	14,695,579	758,691	89,408	14,695,579	
Individual determinants					
Age groups (years) (ref: 0 - 4)					
5-19	1.15 (1.12, 1.18)	1.92 (1.66, 2.23)	2.93 (1.75, 4.91)	1.72 (1.48, 1.99)	
20-34	4.13 (4.05, 4.22)	2.00 (1.75, 2.30)	4.02 (2.47, 6.55)	7.01 (6.12, 8.04)	
35-49	4.13 (4.05, 4.21)	1.98 (1.72, 2.27)	4.20 (2.58, 6.84)	6.73 (5.87, 7.71)	
50-64	4.20 (4.12, 4.29)	2.01 (1.75, 2.31)	5.46 (3.35, 8.90)	6.98 (6.08, 8.00)	
65-74	3.03 (2.97, 3.10)	1.60 (1.38, 1.85)	5.05 (3.07, 8.31)	3.94 (3.41, 4.55)	
75-84	3.00 (2.94, 3.07)	1.61 (1.38, 1.87)	5.37 (3.23, 8.93)	3.86 (3.33, 4.48)	
≥85	5.57 (5.45, 5.70)	1.72 (1.48, 2.01)	5.95 (3.57, 9.92)	7.09 (6.08, 8.26)	
Male sex	0.76 (0.76, 0.76)	1.26 (1.23, 1.30)	1.35 (1.26, 1.44)	1.00 (0.98, 1.03)	
Living in rural/small town ^b	0.97 (0.96, 0.98)	0.81 (0.74, 0.88)	0.76 (0.65, 0.88)	0.76 (0.70, 0.83)	
Public Health region (ref: Toronto)	,		,	,	
Central East	1.12 (1.10, 1.14)	0.40 (0.36, 0.45)	0.54 (0.42, 0.71)	0.44 (0.39, 0.50)	
Central West	0.97 (0.96, 0.98)	0.61 (0.57, 0.65)	0.91 (0.78, 1.07)	0.58 (0.55, 0.62)	
Durham	0.87 (0.86, 0.88)	0.95 (0.88, 1.02)	1.55 (1.24, 1.94)	0.81 (0.76, 0.87)	
Eastern	1.06 (1.05, 1.08)	0.33 (0.29, 0.38)	0.39 (0.30, 0.51)	0.35 (0.31, 0.39)	
North	1.19 (1.17, 1.21)	0.19 (0.16, 0.22)	0.30 (0.23, 0.39)	0.23 (0.19, 0.26)	
Ottawa	0.97 (0.95, 0.99)	0.82 (0.75, 0.91)	1.06 (0.82, 1.37)	0.78 (0.70, 0.86)	
Peel	0.98 (0.97, 0.99)	0.99 (0.95, 1.04)	0.75 (0.65, 0.87)	0.95 (0.91, 0.99)	
South West	0.99 (0.98, 1.01)	0.61 (0.56, 0.66)	1.22 (1.01, 1.47)	0.60 (0.56, 0.65)	
York	0.89 (0.88, 0.90)	0.88 (0.83, 0.93)	1.03 (0.88, 1.20)	0.77 (0.72, 0.81)	
Underlying chronic health conditions					
Asthma	1.09 (1.09, 1.10)	0.86 (0.83, 0.89)	0.85 (0.78, 0.93)	0.93 (0.89, 0.96)	
COPD	1.23 (1.21, 1.24)	0.89 (0.82, 0.96)	0.83 (0.70, 0.98)	1.05 (0.97, 1.13)	
Hypertension	0.98 (0.98, 0.99)	1.12 (1.08, 1.16)	1.10 (1.00, 1.20)	1.13 (1.09, 1.18)	
Diabetes	0.98 (0.97, 0.99)	1.26 (1.21, 1.31)	1.18 (1.07, 1.30)	1.19 (1.15, 1.24)	
Congestive heart failure	1.26 (1.24, 1.28)	0.99 (0.92, 1.07)	0.92 (0.77, 1.11)	1.25 (1.16, 1.35)	


Dementia or frailty score >15	2.12 (2.09, 2.15)	1.38 (1.29, 1.49)	1.69 (1.44, 1.98)	2.59 (2.41, 2.79)
Cancer ^c	1.13 (1.12, 1.15)	0.72 (0.66, 0.80)	0.87 (0.70, 1.09)	0.85 (0.78, 0.94)
Chronic kidney disease ^c	1.31 (1.29, 1.32)	0.86 (0.80, 0.93)	1.04 (0.88, 1.23)	1.16 (1.08, 1.24)
Immunocompromised ^d	1.30 (1.28, 1.33)	0.79 (0.70, 0.89)	0.84 (0.63, 1.10)	1.02 (0.91, 1.14)
Advanced liver disease	1.14 (1.11, 1.16)	0.78 (0.68, 0.90)	0.76 (0.54, 1.07)	0.87 (0.76, 1.00)
Ischemic heart disease	1.02 (1.01, 1.03)	0.88 (0.82, 0.95)	0.81 (0.68, 0.97)	0.90 (0.84, 0.97)
Ischemic stroke or TIA ^e	1.15 (1.13, 1.17)	1.05 (0.95, 1.17)	0.94 (0.73, 1.20)	1.18 (1.06, 1.31)
Schizophrenia [†]	1.24 (1.21, 1.27)	0.84 (0.73, 0.96)	1.28 (0.92, 1.77)	0.99 (0.86, 1.13)
Substance abuse ^t	1.17 (1.16, 1.19)	0.72 (0.65, 0.79)	0.52 (0.40, 0.68)	0.86 (0.78, 0.94)
Healthcare use	1.17 (1.10, 1.19)	0.72 (0.05, 0.79)	0.32 (0.40, 0.00)	0.80 (0.78, 0.94)
Aggregated Diagnostic Group quintile (ref:				
0 ADGs)				
2 (1-2 ADGs)	1.64 (1.62, 1.66)	0.78 (0.74, 0.84)	0.68 (0.58, 0.81)	1.24 (1.17, 1.32)
3 (3-4 ADGs)	2.07 (2.04, 2.10)	0.75 (0.70, 0.80)	0.57 (0.48, 0.68)	1.47 (1.37, 1.57)
4 (5-6 ADGs)	2.45 (2.41, 2.48)	0.74 (0.69, 0.79)	0.56 (0.47, 0.68)	1.69 (1.58, 1.82)
5 (7-27 ADGs)	3.11 (3.06, 3.15)	0.75 (0.69, 0.80)	0.52 (0.43, 0.63)	2.13 (1.98, 2.29)
Hospital admissions, past 3 years (ref: 0 admissions)				
1	0.99 (0.98, 1.00)	0.93 (0.89, 0.97)	0.88 (0.79, 0.98)	0.92 (0.88, 0.96)
2	1.16 (1.14, 1.17)	0.86 (0.79, 0.93)	0.80 (0.66, 0.97)	1.01 (0.94, 1.09)
≥3	1.75 (1.73, 1.78)	0.82 (0.76, 0.90)	1.04 (0.86, 1.26)	1.38 (1.27, 1.50)
Outpatient physician visits, past year (ref: 0 – 1 visits)				
2 – 4	1.08 (1.07, 1.09)	1.02 (0.98, 1.07)	1.07 (0.95, 1.19)	1.12 (1.08, 1.18)
5 – 8	1.11 (1.10, 1.12)	1.03 (0.98, 1.08)	1.01 (0.89, 1.15)	1.17 (1.11, 1.23)
9 – 14	1.17 (1.16, 1.18)	0.98 (0.93, 1.04)	1.04 (0.90, 1.20)	1.17 (1.10, 1.24)
≥15	1.36 (1.34, 1.37)	0.91 (0.85, 0.97)	0.88 (0.75, 1.03)	1.22 (1.14, 1.30)
Influenza vaccination (2019-2020 season)	1.08 (1.08, 1.09)	0.81 (0.78, 0.83)	0.86 (0.79, 0.93)	0.87 (0.84, 0.90)
Environmental determinants ^g	,	,	, , ,	
PM _{2.5} category (μg/m ³) (ref: 2 – 6)				
6-7	0.97 (0.96, 0.98)	0.91 (0.84, 0.98)	0.81 (0.69, 0.96)	0.92 (0.85, 0.99)
7-8	0.91 (0.90, 0.92)	1.05 (0.95, 1.16)	0.99 (0.80, 1.22)	0.96 (0.87, 1.06)
8-9	0.90 (0.89, 0.92)	1.24 (1.11, 1.37)	1.15 (0.93, 1.43)	1.15 (1.04, 1.27)
≥10	0.89 (0.88, 0.91)	1.37 (1.22, 1.55)	1.49 (1.18, 1.90)	1.24 (1.10, 1.39)
NO ₂ category (parts per billion) (ref: 0 – 6)	,			,
6-8	0.96 (0.95, 0.96)	1.05 (1.00, 1.11)	1.05 (0.94, 1.16)	1.00 (0.95, 1.05)
≥8	0.93 (0.92, 0.95)	1.12 (1.05, 1.19)	1.08 (0.93, 1.26)	1.03 (0.97, 1.10)
Social determinants of health ^h (area-level)	,			
Household income quintile (ref: 1st quintile,				

lowest income)				
2	1.03 (1.02, 1.04)	0.98 (0.93, 1.03)	0.95 (0.84, 1.08)	1.02 (0.97, 1.06)
3	1.09 (1.08, 1.10)	1.06 (0.99, 1.12)	0.96 (0.82, 1.12)	1.13 (1.07, 1.20)
4	1.11 (1.10, 1.13)	1.02 (0.95, 1.09)	0.95 (0.80, 1.12)	1.09 (1.02, 1.17)
5 (highest income)	1.12 (1.10, 1.14)	1.00 (0.92, 1.08)	1.22 (1.01, 1.47)	1.08 (1.00, 1.16)
Social assistance quintile (ref: 1st quintile)				
2	1.03 (1.02, 1.04)	1.11 (1.06, 1.16)	1.04 (0.93, 1.16)	1.12 (1.07, 1.18)
3	1.04 (1.04, 1.05)	1.19 (1.14, 1.26)	1.15 (1.02, 1.29)	1.22 (1.16, 1.28)
4	1.05 (1.04, 1.06)	1.20 (1.14, 1.27)	1.09 (0.96, 1.25)	1.22 (1.16, 1.30)
5	1.05 (1.04, 1.06)	1.36 (1.27, 1.45)	1.11 (0.95, 1.30)	1.38 (1.30, 1.47)
Limited educational attainment quintile (ref: 1 st quintile)	,			
2	1.04 (1.03, 1.04)	1.11 (1.06, 1.16)	1.13 (1.01, 1.26)	1.15 (1.10, 1.20)
3	1.02 (1.02, 1.03)	1.23 (1.17, 1.29)	1.21 (1.08, 1.36)	1.26 (1.21, 1.33)
4	1.03 (1.02, 1.04)	1.33 (1.27, 1.40)	1.46 (1.29, 1.65)	1.36 (1.30, 1.43)
5	1.02 (1.01, 1.03)	1.49 (1.41, 1.58)	1.50 (1.31, 1.72)	1.52 (1.44, 1.60)
Uncoupled quintile ^k (ref: 1 st quintile)				
2	1.02 (1.01, 1.03)	0.96 (0.91, 1.01)	1.06 (0.96, 1.18)	0.97 (0.93, 1.02)
3	1.07 (1.06, 1.08)	0.96 (0.92, 1.01)	1.00 (0.88, 1.12)	1.01 (0.96, 1.06)
4	1.20 (1.18, 1.21)	0.98 (0.93, 1.04)	0.95 (0.83, 1.09)	1.14 (1.08, 1.21)
5	1.39 (1.38, 1.41)	1.09 (1.03, 1.17)	1.06 (0.91, 1.25)	1.46 (1.37, 1.56)
Household density quintile (ref: 1st quintile)				
2	1.02 (1.01, 1.02)	1.25 (1.19, 1.32)	1.24 (1.10, 1.40)	1.25 (1.19, 1.32)
3	1.04 (1.03, 1.05)	1.48 (1.40, 1.57)	1.36 (1.18, 1.57)	1.53 (1.45, 1.62)
4	1.03 (1.02, 1.04)	1.84 (1.74, 1.94)	1.82 (1.59, 2.09)	1.89 (1.79, 1.99)
5	0.98 (0.97, 0.99)	2.12 (1.99, 2.26)	1.74 (1.47, 2.05)	2.08 (1.95, 2.21)
Apartment building density category ^m (ref: 1 st category)				
2	1.03 (1.03, 1.04)	0.98 (0.94, 1.03)	1.00 (0.90, 1.10)	1.00 (0.96, 1.04)
3	1.02 (1.01, 1.03)	1.13 (1.08, 1.20)	1.08 (0.94, 1.24)	1.16 (1.10, 1.22)
Recent immigration category ⁿ (ref: 1 st category)				
2	1.00 (0.99, 1.00)	1.05 (1.00, 1.09)	1.12 (1.02, 1.23)	1.04 (1.00, 1.08)
3	0.94 (0.94, 0.95)	1.18 (1.12, 1.23)	1.31 (1.17, 1.47)	1.12 (1.07, 1.16)
Visible minority quintile ^o (ref: 1 st category)				
2	0.99 (0.98, 0.99)	0.94 (0.88, 1.01)	1.02 (0.90, 1.16)	0.94 (0.88, 1.00)
3	0.94 (0.93, 0.95)	0.94 (0.88, 1.01)	1.04 (0.91, 1.20)	0.89 (0.83, 0.96)
4	0.91 (0.90, 0.92)	1.03 (0.96, 1.11)	1.10 (0.94, 1.29)	0.94 (0.87, 1.01)
5	0.85 (0.84, 0.87)	1.22 (1.12, 1.33)	1.15 (0.95, 1.39)	1.03 (0.95, 1.12)

- ^a Fully-adjusted analyses contain as covariates all variables listed in this table.
- "Rural" defined as located outside the commuting zone of a city with greater than 10,000 population.
- ^b Participants were counted if they had a diagnosis in the last 5 years.
- ^c Participants considered "immunocompromised" if they were HIV positive, or had an organ or bone marrow transplant, or another immunodeficient condition.
- ^d This category includes individuals with ischemic stroke or TIA in the last 20 years.
- ^e This category includes individuals with a diagnosis in the last 2 years.
- $^{\rm f}$ Values of PM_{2.5} > 12µg/m³ or NO₂ > 53ppb yearly has been found to be associated with increased risk of other respiratory illnesses.⁸⁰
- ⁹ All variables in this category are area-level variables at the level of the Census Dissemination Area.
- h 1st quintile represents 38.0 63.5% of individuals in the area receiving governmental transfer payments; 2nd quintile: 63.5 67.2% of individuals; 3rd quintile: 67.2 70.8% of individuals; 4th quintile: 70.8 75.3% of individuals; 5th quintile: 75.3 98.1% of individuals.
- i 1st quintile represents 0 4.1% of individuals 25-64 years old without diploma; 2nd quintile: 4.1 7.5% of individuals; 3rd quintile: 7.5 11.4% of individuals; 4th quintile: 11.4 17.1% of individuals; 5th quintile: 17.1 94.3% of individuals.


 j 1st quintile represents 11.2 33.7% individuals uncoupled; 2nd quintile: 33.7 38.4% individuals; 3rd quintile: 38.5 –
- 43.6% individuals; 4th quintile: 43.6 51.0% individuals; 5th quintile: 51.0 94.6% individuals.
- ^k 1st quintile represents 0-2.1 persons/dwelling; 2nd quintile: 2.2 2.4 persons/dwelling; 3rd quintile: 2.5 2.6 persons/dwelling; 4th quintile: 2.7 3 persons/dwelling; 5th quintile: 3.1 5.7 persons/dwelling.
- 1st category represents 0 7.3% of buildings in the area being apartment buildings; 2nd category: 7.4 37.7% of buildings; 3rd category: 37.7 100% of buildings.
- m 1st category represents 0 2.1% of individuals in DA being recent immigrants; 2nd category: 2.1 4.7% of individuals; 3rd category: 4.7 41.2% of individuals.
- n 1st quintile represents 0 2.2% of individuals in the area self-identifying as a visible minority; 2nd quintile: 2.2 7.5% of individuals; 3rd quintile: 7.5 18.7% of individuals; 4th quintile: 18.7 43.5% of individuals; 5th quintile: 43.5 100% of individuals.

Figure 1. Diagram of inclusion and exclusion criteria and resulting analytic datasets.




Individuals were excluded if they had a listed age >105 years, had a listed postal code outside of Ontario, or had no record of contact with the healthcare system in the past 8 years (since March 2012).

Figure 2. Unadjusted, sex/age adjusted, and fully adjusted association between social determinants and SARS-CoV-2 testing (panel A) and COVID-19 diagnosis (panel B), using the case-control design, in Ontario (March 1 to June 20, 2020).



Forest plots show the odds of being tested for SARS-CoV-2, compared to the reference group (1st quintile or 1st category). In all cases, the first quintile/category represents the lowest quintile of values for the variable at the dissemination area (DA)-level. For example, the lowest quintile of household income represents individuals living in the lowest 20% of DAs by income quintile. Age/sexadjusted models are shown in Table 2. Fully-adjusted models control for all variables listed in Table 2, including (but not limited to) all variables shown in this figure; effect estimates and 95% Os for all models shown here can be found in eTable 2.



Forest plots show the odds of being tested for SARS-CoV-2, compared to the reference group (1st quintile or 1st category). In all cases, the first quintile/category represents the lowest quintile of values for the variable at the dissemination (DA)-level. For example, the lowest quintile of DA-level income represents individuals living in the lowest 20% of DAs by income quintile. Fully-adjusted models are shown in the rightmost column of Table 2 and control for all variables listed in Table 2, including (but not limited to) all variables shown in this figure. Effect estimates and 95% CIs for all models shown here can be found in eTable 5.